ATRA and Anthracycline based treatment in APL Ramzi Jeddi, ESH 28-30 October 2010.

Slides:



Advertisements
Similar presentations
Acute promyelocytic leukemia
Advertisements

Acute Promyelocytic Leukemia
The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.
Chronic Myeloid Leukemia: Treatment Success and Milestones
Breakthroughs in the treatment of acute promyelocytic leukemia: curable disease with retinoic and arsenic Jiong HU Shanghai Institute of Hematology, Department.
Induction Therapies in Transplant Eligible Patients Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College.
Pierre Fenaux (Hopital Avicenne,Paris 13 University)
Stock W et al. Proc ASH 2014;Abstract 796.
Results of a Phase 2 Randomised, Open- Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory.
Hematologic Malignancies
Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)
Copyright © 2011 Research To Practice. All rights reserved. Interest in Topics Related to the Treatment of Patients with CLL (Percent Responding 9 or 10)
Arsenic Trioxide (ATO) in the Consolidation Treatment of Newly Diagnosed APL — First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian.
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
Cord blood selection, release, and transplantation 6th World Congress Tissue Banking Barcelona, Spain, 10 November 2011 Guillermo Sanz Hospital Universitari.
Acute Promyelocytic Leukemia (APL)
Risk Stratification of Patients with Myelofibrosis and the Role of Transplant Alessandro M. Vannucchi Section of Hematology, University of Florence, Italy.
LIBYAN EXPERIENCE IN PEDIATRIC ACUTE MYELOID LEUKEMIA Fathia El Riani, Rasem Al Ajnef, Elham Sbita, Salem Zarroug Departement of pediatric hematology-oncology.
영남대학교 의과대학 혈액종양내과 현 명 수 Curative Strategies in Acute Promyelocytic Leukemia.
Current Status of Acute Myeloid Leukemia in China Jianxiang Wang Institute of Hematology Hospital of Blood Disease Chinese Academy of Medical Sciences.
Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.
Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.
Best of ASH 2007 Acute Leukemias Charles Linker MD #439Tipifarnib for elderly AML #593Combination arsenic & ATRA for APL #297NPM predicts ATRA response.
ICCS e-Newsletter CSI Fall 2010 David D. Grier, M.D. Department of Pathology. Wake Forest University.
Complete Hematological Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon -2a (peg-IFN-2a) Therapy.
Sergio Giralt defends the PRO position To Maintain or Not to Maintain The Answer is Yes And Lenalidomide is the Right Choice.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
SCIENCE MEETS MEDICINE: ACUTE PROMYELOCYTIC LEUKEMIA Nancy Fuller, M.D. June 23, 2004.
Long-term Outcome after hyper-CVAD and Imatinib for De Novo or Minimally Treated Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph-ALL)
Inotuzumab Ozogamicin (IO; CMC544), a CD22 Monoclonal Antibody Attached to Calicheamycin, Produces Complete Response (CR) plus Complete Marrow Response.
PATH 430 MOLECULAR BASIS OF DISEASE MICHAEL RAUH, MD, PHD JANUARY 18, 2016.
What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy? Radioimmunotherapy! Matthew Matasar,
Best of ASH 2007 Myelodysplastic Syndromes Lloyd E. Damon, MD.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Results from a Randomized Phase III Trial of Decitabine versus Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed.
Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:
林建廷. Cancer 2006;106:2657–63 55% 34% 5% OS 25%Ph+ Standard risk High risk All pts cHR pts Risk stratification at diagnosis.
ANCO 2006 ASH UPDATE MDS Joseph M. Tuscano, M.D. UC Davis Cancer Center.
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
Society for Hematopathology/ European Association for Haematopathology Case 211 Rachel Ochs, MD Adam Bagg, MD Hospital of the University of Pennsylvania.
Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML) Cashen.
May 29 - June 2, 2015 Leukemia Stem Cell Phenotypes Correlate With Cytogenetic Risk Factors and Outcomes CCO Independent Conference Highlights of the 2015.
ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL New Findings in Hematology: Independent Conference.
Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma New Findings in Hematology: Independent.
Geisler C et al. Proc ASH 2011;Abstract 290.
39th ESMO Congress Madrid, Spain – 30 September Poster 979P
New Findings in Hematology: Independent Conference Coverage
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
Palumbo A et al. Proc ASH 2012;Abstract 200.
Maury S et al. Proc ASH 2015;Abstract 1.
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
CCO Independent Conference Highlights
Clinical Focus: Acute Promyelocytic Leukemia
Platzbecker U et al. Proc ASH 2014;Abstract 12.
REVIEW AML RECURRENCE R3 조경민.
Oki Y et al. Proc ASH 2013;Abstract 252.
Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.
ASCT for AL Seok Jin Kim
New Findings in Hematology: Independent Conference Coverage
Fenaux P et al. Lancet Oncol 2009;10(3):
Case:2 leukemia دينا نعمان جرادة جيهان ايمن مقاط.
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results by Lionel Adès, Miguel A. Sanz,
Grövdal M et al. Blood 2008;112:Abstract 223.
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Anas Younes, M.D. Memorial Sloan Kettering Cancer Center
Case study 14 Hadeel , Huda , Abeer.
Kantarjian HM et al. Blood 2008;112:Abstract 635.
Presentation transcript:

ATRA and Anthracycline based treatment in APL Ramzi Jeddi, ESH October 2010

Treatment Treatment From 2004… From 2004… APL diagnoses APL diagnoses European APL 93 Fenaux et al Fenaux et al Spanish PETHEMA LPA99 Sanz et al Sanz et al Morphology Auer rods,hypergranular,microgranular Cytogenetic analysis t(15;17) since 1997 Molecular analysis RT-PCR PML/RARA since 2004 ATRA era since 1998 Fenaux P Blood 1999;14: Sanz MA Blood 2004;103:

European APL 93  65yr and i WBC<5 >65yr or i WBC>5 ATRA CT ATRA + CT3 ATRA + CT1 AB C CT=Ara-C+DNR

Patients,n34 M15 F19 Age,median,range28(6-60) WBC,median,range3(0.6-97) Morphology Hypergranular33 Variant1 Add. cytog. abn.26,4% Sanz’s score Low32% Intermediaite High 53% 15% CR82% Early death18% Results with European APL 93 (Tunis,n=24,Sfax,n=10)

Age,yr Sanz’s scoreHRRI HR IFCD2 - CD56 - CD2 - CD56 - NA Median,month siteMMM+CNSM Salvage therapyAPL93LPA99APL93 OutcomeDeathAliveDeath Relapse rate =14.2% ASCT PML/RARA-

From 2004… Spanish PETHEMA LPA 99 Spanish Contribution to APL treatment No AraC!

Complete remission

Mortality rate

Failure in LPA 99=Early Death HemorrhageDS

Hemorrhage Breccia M Haematologica 2010;853-4

In our study Median time from first sign and treatment 18 days (range,3-90)

Differentiation syndrome

11 pts with DS Moderate=4 Severe=7 Mortality=3

BMI> 30 Baseline WBC > 20

BMI> 30 Baseline WBC > 20 Normal Promyelocytes APL cells OB_Rs

BMI> 30 Baseline WBC > 20 Normal Promyelocytes APL cells OB_Rs Adipose tissue

BMI> 30 Baseline WBC > 20 Normal Promyelocytes APL cells OB_Rs Adipose tissue Leptin

BMI> 30 Baseline WBC > 20 Normal Promyelocytes APL cells OB_Rs Adipose tissue Leptin Release of cytokines

BMI> 30 Baseline WBC > 20 Normal Promyelocytes APL cells OB_Rs Adipose tisuue Leptin Release of cytokines DS

confirmed in larger series > 1000 pts Included in APL93 & APL2000 and will be presented as poster in ASH Annual meeting 2010

Relapse rate

Childhood APL Jeddi R.Med Oncol Aug 10

65 APL pts 20 Children45 Adults APL93 6 LPA99 14 LPA99 27 APL93 18 ATRA dose=25mg/m2

Children vs Adults

GIMEMA

Emerging problem?

Cumulative dose of Anthracycline - IDA =90mg/m2 - MTZ=50mg/m2

APL in children

Our series (2010) ATRA+CT 20 12(4-19) NA US intergroup 0129 ATRA vs No ATRA

APL in children Our series (2010) ATRA+CT 20 12(4-19) NA US intergroup 0129 ATRA vs No ATRA

APL in children Our series (2010) ATRA+CT 20 12(4-19) NA US intergroup 0129 ATRA vs No ATRA

APL in children Our series (2010) ATRA+CT 20 12(4-19) NA US intergroup 0129 ATRA vs No ATRA

Conclusions - Acceptable results - Improvement is required: * reach CR of 90% in adults * reach CR of 90% in adults * Maintain OS between 75-80% * Maintain OS between 75-80% - Availability of ATO for relapses

Aknowledgment Balkis Meddeb Hèla Ben Abid Zaher Belhadjali Raihane Ben Lakhal Hdiji Sondes Raouf Hafsia Emna Gouider Samia Ménif Lamia Aissaoui Ramzi Ben Amor Karima Kacem Walid Boutéraa Yosr Ben Abdennebi Héla Ghédira Pierre Fenaux Miguel Sanz